| Synonyms: | |
| Status: | Approved (2023) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| UNII: | QZ62892OFJ |
| InChI Key | VFCRKLWBYMDAED-REWPJTCUSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C27H41F2N5O |
| Molecular Weight | 489.66 |
| AlogP | 4.79 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 10.0 |
| Polar Surface Area | 70.98 |
| Molecular species | BASE |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 35.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Protease
Aspartic protease
Aspartic protease AD clan
Aspartic protease A22A subfamily
Aspartic protease A22A regulatory subfamily
|
- | 1-19 | - | - | - | |
|
Enzyme
|
- | 1-19 | - | - | - | |
|
Ion channel
Other ion channel
Miscellaneous ion channel
Presenilin ER Ca2+ leak channel family
|
- | 1-19 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Fibromatosis, Aggressive | 3 | D018222 | ClinicalTrials |
| Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Multiple Myeloma | 1 | D009101 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL1770916 |
| DrugBank | DB12005 |
| EPA CompTox | DTXSID60235679 |
| FDA SRS | QZ62892OFJ |
| Guide to Pharmacology | 7746 |
| PubChem | 46224413 |
| SureChEMBL | SCHEMBL13184754 |
| ZINC | ZINC000038217837 |